Daiichi Sankyo Europe

What Daiichi Sankyo Europe does

Daiichi Sankyo Europe GmbH is the European operating division of Daiichi Sankyo Co. Ltd., a Japanese-headquartered global pharmaceutical company. Established in 2006 and headquartered in Munich, Germany, the entity operates as a private limited company with a wholly-owned subsidiary structure and national affiliates across at least twelve European countries (Germany, France, UK, Italy, Spain, Netherlands, Austria, Sweden, Portugal, Belgium, Switzerland, and Greece). The European headquarters is located at Zielstattstrasse 48, Munich, with a manufacturing and development site in Pfaffenhofen, Germany. The company employs between 1,001 and 5,000 people and is led by Managing Director Masahiro Kato. Its core purpose is the development and commercialization of pharmaceutical therapies across two therapeutic areas: cardiovascular disease and oncology.

The portfolio is anchored by bempedoic acid, a cholesterol-lowering medication for lipid management in statin-intolerant patients, supported by Phase 3 CLEAR Outcomes trial evidence demonstrating reductions in stroke and venous thromboembolism, pediatric Phase 2 data, and the MILOS real-world registry spanning eight European countries. In oncology, the company leverages parent Daiichi Sankyo's Antibody Drug Conjugate (ADC) technology platform for targeted cancer therapy. In March 2026, the company entered an exclusive strategic partnership with German digital health company GAIA to commercialize lipodia, a cognitive behavioural therapy-based digital therapeutic for hypercholesterolemia, marking its first expansion into digital therapeutics, with planned DiGA reimbursement in Germany. The DSPACE digital innovation hub explores AI applications in cardiology, and patient engagement programs (CardioXplore, CardioConnect) operate under the 'We Care for Every Heartbeat' initiative.

Revenue is generated primarily through prescription pharmaceutical sales (bempedoic acid, oncology portfolio) distributed via standard European pharmaceutical supply chains to hospitals, pharmacies, and healthcare providers. Go-to-market combines enterprise field sales and medical science liaison engagement with event-driven presence at major cardiovascular and oncology congresses (ESC, EAS, ACNAP) and a DocCheck-verified HCP portal for prescription information. Future revenue diversification includes planned statutory health insurance reimbursement via Germany's DiGA pathway for lipodia. Revenue figures for the European subsidiary are not publicly disclosed; financial performance is consolidated at the parent company level (Daiichi Sankyo Co. Ltd., Japan). The customer base is fragmented across patient populations and healthcare providers, with segment focus on cardiovascular patients (high cholesterol, atrial fibrillation), oncology patients (breast, colorectal, lung, gastric cancers), and healthcare professionals served through a hybrid persona and use-case segmentation approach.

Name

Daiichi Sankyo Europe

Legal name

Daiichi Sankyo Europe GmbH

Website

https://daiichi-sankyo.eu

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Daiichi Sankyo Europe GmbH is the European pharmaceutical division of Japan's Daiichi Sankyo Co. Ltd., focused on cardiovascular therapies (bempedoic acid, lipodia digital therapeutic) and oncology (ADC technology), operating across twelve European countries with headquarters in Munich and production in Pfaffenhofen.

Ownership category

akta.pro rank

Product category

Pharmaceuticals (Cardiovascular and Oncology)

NAICS

Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Lipidology & Dyslipidemia (HLAKADAK)

Keywords

• Prescription pharmaceuticals
• Cardiovascular medicines
• Oncology therapeutics
• Antibody drug conjugates
• Digital therapeutics

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Products: Revenue from prescription cardiovascular medicines including bempedoic acid, distributed through standard pharmaceutical supply chains to healthcare providers across Europe.
2. Digital Therapeutics: Planned revenue stream from digital therapeutic lipodia, targeting hypercholesterolemia patients, with planned reimbursement through Germany's DiGA pathway for statutory health insurance coverage.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Daiichi Sankyo Europe develops, manufactures, and distributes prescription pharmaceutical products across two main therapeutic areas: Cardiovascular (bempedoic acid for lipid management in statin-intolerant patients, plus cardiovascular patient engagement programs) and Oncology (using its proprietary ADC technology platform for targeted cancer therapies). The company is expanding its offering into digital therapeutics through an exclusive European partnership with GAIA for lipodia, a cognitive behavioural therapy-based digital therapeutic for adults with hypercholesterolemia, planned for launch in Germany via the DiGA pathway.

Product overview

Daiichi Sankyo Europe operates as a pharmaceutical company with two core therapeutic areas: Cardiovascular and Oncology. In Cardiovascular, the portfolio includes bempedoic acid for lipid management in statin-intolerant patients, and the digital therapeutic lipodia (in partnership with GAIA) using cognitive behavioural therapy for hypercholesterolemia management. The company also runs patient programs like CardioXplore and CardioConnect under its 'We Care for Every Heartbeat' initiative. In Oncology, the company focuses on ADC (Antibody Drug Conjugate) technology for targeted cancer therapies and maintains various cancer awareness initiatives. DSPACE serves as the company's digital innovation hub exploring AI applications in cardiology. The company supports clinical research including the CLEAR Outcomes trial and MILOS registry, and partners with patient organizations like Global Heart Hub.

Differentiator

Problem solved

Functional benefit

Brands

• DSPACE: Daiichi Sankyo's digital innovation hub focused on developing digital health solutions and exploring AI applications in cardiology.
• We Care for Every Heartbeat
• CardioXplore
• CardioConnect

Products and services

• Bempedoic Acid A prescription cholesterol-lowering medication for lipid management in statin-intolerant patients, including those with heterozygous familial hypercholesterolemia (including pediatric patients aged 6-17). Demonstrated in the Phase 3 CLEAR Outcomes trial to reduce cardiovascular risks such as stroke and venous thromboembolism, and supported by MILOS real-world evidence across eight European countries. Distributed through standard European pharmaceutical supply chains to hospitals, pharmacies, and healthcare providers.
• Lipodia Digital Therapeutic A next-generation digital therapeutic for adults with hypercholesterolemia, using cognitive behavioural therapy techniques to support cholesterol management when added to standard pharmacological therapy. Currently in Phase 3 DIGICHOL trial with 272 subjects. To be commercialized by Daiichi Sankyo Europe under exclusive license from GAIA, with planned reimbursement via Germany's DiGA pathway and expansion mechanisms for other major European markets.
• ADC Technology Platform (Oncology Portfolio) Daiichi Sankyo's proprietary Antibody Drug Conjugate (ADC) technology platform for targeted cancer therapy, forming the backbone of the company's oncology portfolio and enabling personalized oncology treatment approaches.

Quantifiable outcome

• Bempedoic acid demonstrated effectiveness in reducing cardiovascular risks including stroke and venous thromboembolism in statin-intolerant patients (CLEAR Outcomes trial)
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• GAIAcoreStrategic or Co-development Partner · 5 March 2026Exclusive strategic partnership to commercialize lipodia, a next-generation digital therapeutic for adults with hypercholesterolemia. Daiichi Sankyo gains exclusive rights in Europe, launching initially in Germany. GAIA plans to submit for reimbursement through Germany's DiGA pathway following Phase 3 RCT (DIGICHOL) data. This is Daiichi Sankyo's first expansion into the DTx arena as part of its cardiovascular portfolio.
• Esperion TherapeuticscoreStrategic or Co-development PartnerCollaboration on Phase 3 CLEAR Outcomes trial for bempedoic acid, with post-hoc analyses presented at EAS Congress 2026 demonstrating drug effectiveness in reducing cardiovascular risks including stroke and venous thromboembolism in statin-intolerant patients.
• Global Heart HubcoreStrategic or Co-development PartnerPatient advocacy partnership focused on women and cardiovascular disease. Daiichi Sankyo supports GHH's International Roundtable on late/missed diagnosis of heart disease in women, and a 1-year research project exploring women's experiences with cardiovascular symptoms and healthcare biases.
• AmgenminorStrategic or Co-development PartnerResearch supporter alongside Daiichi Sankyo Europe and Novartis Pharmaceuticals for IPEC2 patient-led research study on women's cardiovascular care presented at ACNAP Congress 2026.
• Novartis PharmaceuticalsminorStrategic or Co-development PartnerResearch supporter alongside Daiichi Sankyo Europe and Amgen for IPEC2 patient-led research study on women's cardiovascular care presented at ACNAP Congress 2026.
• Women as OnecoreStrategic or Co-development PartnerPartnership addressing gender disparities in cardiovascular research and care by elevating female clinicians, promoting gender-equitable research, and addressing unique risks women face in cardiovascular health.
• AF AssociationcoreGTM or Marketing PartnerCo-design and co-run Advisory Board with AF Association to learn from people living with atrial fibrillation about their experiences and perspectives, supporting Global AF Aware Week initiatives.
• Fight Colorectal CancerminorGTM or Marketing PartnerLongtime partner for Colorectal Cancer Awareness Month, supporting Strong Arm Selfie campaign and raising awareness of risk factors and improved access to screenings.
• Colorectal Cancer AllianceminorGTM or Marketing PartnerLongtime partner for Colorectal Cancer Awareness Month supporting awareness campaigns.
• Digestive Cancers EuropeminorGTM or Marketing PartnerLongtime partner for Colorectal Cancer Awareness Month supporting awareness campaigns and early detection efforts.
• Union for International Cancer Control (UICC)coreStrategic or Co-development PartnerLongtime partner supporting UICC's efforts to address care gaps in cancer, including the Breast Cancer Programme focused on improving quality of life in low- and middle-income countries, and Project ECHO tele-mentoring program.

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Sanofi: French global pharmaceutical company with cardiovascular (Praluent, Multaq) and specialty care franchises plus a growing digital health and vaccines portfolio. Overlapping European cardiovascular footprint and combined pharma-plus-digital strategy parallels Daiichi Sankyo Europe's bempedoic acid/lipodia approach.
• AstraZeneca: British-Swedish pharma with major cardiovascular (Farxiga, Brilinta) and oncology (Enhertu ADC, Tagrisso, Imfinzi) franchises. Direct competitor in European ADC oncology and cardiovascular markets; Enhertu was developed in partnership with the Daiichi Sankyo parent, making it both a peer and a historical partner.
• Novartis: Swiss global pharmaceutical major with deep European cardiovascular (Entresto, Leqvio) and oncology (Pluvicto, Kisqali) portfolios. Comparable to Daiichi Sankyo Europe across both therapeutic pillars and European commercial footprint, including joint research on the IPEC2 women's CV study.
• Pfizer: US-headquartered global pharma with broad cardiovascular (Eliquis via BMS, Vyndaqel) and dominant oncology portfolio including ADC assets acquired through Seagen. Comparable therapeutic area breadth and European commercial scale to Daiichi Sankyo Europe.
• Roche: Swiss global pharma with strong oncology (HER2 franchise, Tecentriq) and cardiovascular diagnostics presence, plus significant investment in digital health and AI applications. Comparable European footprint, oncology depth, and emerging digital health positioning parallel to Daiichi Sankyo's DSPACE and lipodia efforts.
• Boehringer Ingelheim: German privately-held global pharma with strong cardiovascular ( Pradaxa, Jardiance) and oncology presence. Directly comparable European footprint, therapeutic area overlap, and private ownership structure similar to Daiichi Sankyo Europe GmbH.
• Bayer Pharma: German-headquartered global pharma with established cardiovascular franchise (Eliquis via BMS partnership, Xarelto) and growing oncology pipeline. Direct overlap with Daiichi Sankyo Europe's European HQ location and combined CV/oncology positioning.
• Merck KGaA: German-headquartered global science and technology company with healthcare division focused on oncology, neurology, and fertility. Comparable European manufacturing footprint, oncology pipeline overlap, and German corporate base adjacent to Daiichi Sankyo Europe's Munich headquarters.

Direct peers

• Esperion Therapeutics: US biotech that developed bempedoic acid (Nexletol/Nustendi) and is the originator and direct commercial partner of Daiichi Sankyo Europe. Highly comparable product focus on lipid management in statin-intolerant patients, though smaller and US-centric.
• Amgen: US-based biotech with Repatha (PCSK9 inhibitor) directly competing with bempedoic acid in lipid management and LDL-C reduction. Active collaborator on the IPEC2 women's CV research alongside Daiichi Sankyo Europe, making it both a direct competitor in lipid-lowering and a research partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EUdaiichisankyo
• YouTubeyoutube.com/c/daiichisankyoeurope
• LinkedInlinkedin.com/company/daiichi-sankyo-europe-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Daiichi Sankyo Europe